linjc16/ctgov huggingface dataset:
Influence of Anesthesia Methods on Surgical Outcomes and Renal Function

Study Overview
=================
Brief Summary
-----------------
Patients who underwent retrograde intrarenal surgery (RIRS) were randomly allocated to general anesthesia (GA) or spinal anesthesia (SA) groups. Renal function was assessed using estimated glomerular filtration rate, and relative renal function was evaluated using nuclear medicine tests. Maneuverability and accessibility were evaluated after every surgery. We analyzed the influence of anesthesia methods on surgical outcomes and renal function in retrograde intrarenal surgery in a prospective, randomized controlled study.

Official Title
-----------------
Influence of Anesthesia Methods on Surgical Outcomes and Renal Function in Retrograde Intrarenal Stone Surgery: a Prospective, Randomized Controlled Study

Conditions
-----------------
Kidney Calculi

Intervention / Treatment
-----------------
* Procedure: general anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: older than 20 years with renal stones greater than 10 mm Exclusion Criteria: patients who have urologic anatomical abnormalities patients with ASA status ≥ grade III, a contraindication for spinal anesthesia or RIRS, or unexpected intraoperative renal injury

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: general anesthesia<br>general anesthesia | Procedure: general anesthesia<br> <br> * Other names: spinal anesthesia;|
| Other: spinal anesthesia<br>spinal anesthesia | Procedure: general anesthesia<br> <br> * Other names: spinal anesthesia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Renal function change according to anesthesia method | using nuclear medicine tests with diethylenetriamine pentaacetic acid (99m Tc-DTPA) | prior to procedure, and at 3 months after the procedure. |
A Modified Approach for Morbid Obese With Gynecologic Cancer

Study Overview
=================
Brief Summary
-----------------
Comparing standard midline approach with the modified approach in management of morbid obese patients with gynecologic cancers.

Official Title
-----------------
Gynecologic Cancer: a Modified Approach for Morbid Obese Patients

Conditions
-----------------
Malignant Neoplasm of Cervix, Endometrium and Ovary

Intervention / Treatment
-----------------
* Procedure: Approach for cancer resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Resectable (ovarian, endometrial, cervical) cancers. Anaesthetically fit (ASA 1 and 2). Abdominal pannus below symphysis pubis. Exclusion Criteria: Non resectable gynecologic cancer. Unfit patients. Patients who refuse to share in the trial.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Midline approach<br>Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy). | Procedure: Approach for cancer resection<br> <br> |
| Active Comparator: Modified approach<br>Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy). | Procedure: Approach for cancer resection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oncologic outcome | measured by number of lymph nodes retrieved and rate of optimal debulking. | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operative time |  | 1 day | 
| Postoperative procedure related morbidity | Wound and chest complications | 1 month | 
| Blood loss | intraoperative | 1 day | 
| Hospital stay |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gynecologic cancer - panniculectomy
Malnutrition in Chinese Hospitalized Patients and Optimizing the Usage of Nutritional Screening Tools

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is: to diagnose malnutrition in Chinese hospitalized patients with four nutritional screening tools: mini-nutritional assessment - short form, subjective global assessment, malnutrition universal screening tool and nutritional risk screening 2002. to optimize the usage of nutritional screening tools based on data-mining methods.

Conditions
-----------------
Malnutrition

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages≥18; admitted to hospital≥24h and did not receive operation until 8.am next day. Exclusion Criteria: Patients who were pregnant or breast-feeding, and those who could not be interviewed or provide informed consent were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| malnutrition<br> | Other: no intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of malnutrition on admission detected by the four nutritional screening tools | The measure of prevalence of malnutrition on admission is a composite outcome measure. In our study, we used four nutritional screening tools: MUST(malnutrition universal screening tool), SGA(subjective global assessment), MNA-SF(mini-nutritional assessment-short form) and NRS2002(nutritional risk screening 2002) to assess the malnutrition risk among Chinese hospitalized patients. | up to 4 weeks |
Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients

Study Overview
=================
Brief Summary
-----------------
Comparison between the effect of aliskiren/amlodipine combination with amlodipine monotherapy on ankle-foot volume in hypertensive patients. It will be enrolled male or female outpatients, aged 18-65 years.

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: aliskiren/amlodipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diastolic blood pressure > 95 mmHg and < 110 mmHg systolic blood pressure > 140 mmHg and < 180 mmHg no amlodipine therapy for the previous 6 months Exclusion Criteria: diastolic blood pressure > 110 mmHg and or systolic blood pressure > 180 mmHg secondary hypertension heart failure diabetes mellitus liver or kidney diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: aliskiren/amlodipine<br>aliskiren, 300 mg/amlodipine 10 mg | Drug: aliskiren/amlodipine<br>* aliskiren 300 mg /amlodipine 10 mg<br>|
| Active Comparator: amlodipine<br>amlodipine 10 mg | Drug: aliskiren/amlodipine<br>* aliskiren 300 mg /amlodipine 10 mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure, heart rate, ankle-foot volume |  | At baseline, at the end of the wash-out period, after 2, 4, and 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure and heart rate in sitting and standing position |  | At baseline, at the end of the wash-out period, after 2, 4, and 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aliskiren, amlodipine, hypertension, ankle-foot volume, mild and moderate hypertension
Susceptibility to Pathological Gambling

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to assess the risk factors for the development of pathological gambling.

Detailed Description
-----------------
This study will track up to 600 young adults (ages 18 to 29) for a two-year period, collecting variables such as gambling behavior, drug and alcohol use, psychiatry and medical history, family history, impulsivity, quality of life, self-esteem, and cognition. For some individuals who meet criteria as being impulsive, they will be randomized to receive an intervention to help reduce their impulsivity.

Official Title
-----------------
Susceptibility to Pathological Gambling

Conditions
-----------------
Pathological Gambling

Intervention / Treatment
-----------------
* Behavioral: Mindfulness
* Behavioral: Cognition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to understand the procedures and provide written consent Gambled at least 5 times in the past year Between the ages of 18 and 29 at intake Exclusion Criteria: Inability to understand the procedures and provide written consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 29 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Psychoeducation | |
| Active Comparator: Mindfulness<br>Mindfulness activity and psychoeducation | Behavioral: Mindfulness<br>* Subjects receive mindfulness training<br>* Other names: Training;|
| Active Comparator: Cognition<br>Cognitive training and psychoeducation | Behavioral: Cognition<br>* Subject receive cognitive training<br>* Other names: Training;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Structured Clinical Interview for Pathological Gambling (SCI-PG) | The SCI-PG is a validated and reliable scale assessing the presence of DSM-IV criteria for pathological gambling. The number of criteria met for PG is added for a total score and those meeting 5 or more criteria have DSM-IV pathological gambling. Subjects are expected to be followed for the duration of the 3 year study. Diagnostic criteria for pathological gambling every 3 months for the length of the study | Up to 3 years |
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Study Overview
=================
Brief Summary
-----------------
An expanded access program that provides INOpulse treatment to patients with serious disease or conditions associated with pulmonary hypertension associated with pulmonary fibrosis who are not able to participate in the Sponsor's ongoing Phase 3 REBUILD clinical.

Official Title
-----------------
Expanded Access: Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Serious Disease or Conditions Associated With Pulmonary Hypertension

Conditions
-----------------
Pulmonary Fibrosis, Pulmonary Hypertension

Intervention / Treatment
-----------------
* Combination Product: INOpulse


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed Informed Consent Form (and assent as appropriate) prior to the initiation of any study mandated procedures or assessments. Subjects greater than 18 years of age at the time of consent to study participation. Subjects with pulmonary hypertension associated with a disease or condition that are not eligible to participate in current ongoing clinical trials. Subjects are willing and considered in the judgement of the Investigator able to use the INOpulse device continuously for up to 24 hours per day. Female patients of childbearing potential must have a negative pre-treatment pregnancy test (serum or urine). All female patients should take adequate precaution to avoid pregnancy. Subjects, in the opinion of the Investigator that would benefit from iNO treatment. Exclusion Criteria: Subjects who require treatment with riociguat. Clinical contraindication to inhaled nitric oxide, as deemed by the Investigator. Subjects who require concurrent Positive Airway Pressure (PAP) or Positive End Expiratory Pressure (PEEP). Concurrent use of benzocaine, dapsone, nitrites and nitrates (amyl nitrite, isosorbide, nitroglycerin, nitroprusside), phenazopyridine. or primaquine.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Combination Product: INOpulse|Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PF, Pulmonary Fibrosis, Pulmonary Hypertension, PH, Inhaled Nitric Oxide, iNO, Long Term Oxygen Therapy, LTOT, Oxygen, INOpulse, pulsed inhaled nitric oxide, fILD, fibrotic interstitial lung disease, portable pulsed inhaled nitric oxide
Postmarketing Surveillance Study With MOBEC®

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the indication for MOBEC in a dose of 15 mg per day the treatments patients were receiving before switching to 15 mg MOBEC how treatment with 15 mg is assessed compared with previous treatment how effective and safe treatment with 15 mg MOBEC is considered

Official Title
-----------------
COX-2 Postmarketing Surveillance Study With MOBEC® 15 mg Tablets

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: MOBEC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: An indication for a treatment with 15 mg MOBEC of at least four weeks the symptomatic short-term treatment of osteoarthritis the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg) the symptomatic treatment of ankylosing spondylitis Exclusion Criteria: Treatment with MOBEC prior to the start of the study Patients with any of the general or specific contraindications of MOBEC
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MOBEC<br> | Drug: MOBEC<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nature and incidence of adverse drug reactions (ADR) |  | up to week 8 | 
| Assessment of efficacy by physician on a 5-point scale |  | up to week 8 | 
| Assessment of tolerability by physician on a 5-point scale |  | up to week 8 |
Transfer to Another Health Care Facility Following Critical Illness

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify acute and chronic medical conditions that are identifiable early in the course of critical illness that are associated with transfer to another health care facility (versus to home) upon hospital discharge.

Detailed Description
-----------------
Many patients who survive critical illness are unable to return home upon hospital discharge and require prolonged or permanent care in other health care facilities. It would be useful to clinicians, researchers, patients, and patients' families to be able to identify early in the course of critical illness those patients who are at increased risk for this outcome. Currently, few data exist regarding the risk factors for this outcome. This study examines a cohort of survivors of critical illness to identify factors associated with transfer to another health care facility upon hospital discharge.

Official Title
-----------------
Transfer to Another Health Care Facility Following Critical Illness

Conditions
-----------------
Transfer to a Health Care Facility After Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admission to the University of Chicago Medical Intensive Care Unit during the following periods: July 1997 to February 1998, November/December 2001, and March/April 2002. Exclusion Criteria: Death during the index hospitalization. Residence in another health care facility 2 weeks prior to admission.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic critical illness, Functional status, Outcomes, Post-ICU
Clinical and Radiographic Outcomes of Dental Implant Therapy

Study Overview
=================
Brief Summary
-----------------
900 subjects having received dental implants 9-10 years ago are invited for a clinical and radiographic examination. The individuals were randomly selected from the National Health Insurance data register in Sweden. The clinical and radiographic examination of the 900 selected subjects will include assessments of implant loss, loss of prosthesis and technical / biological complications. Biological complications will be assessed from the findings in the clinical and radiographic examinations. Thus, signs of pathology in peri-implant tissues, probing pocket depth (PPD) and bleeding/pus on probing (BoP) will be recorded. Marginal bone loss and other findings in radiographs will also be evaluated. The prevalence, extent and severity of peri-implantitis will hereby be determined. Patient-centered outcomes will also be obtained.

Official Title
-----------------
Clinical and Radiographic Outcomes of Dental Implant Therapy

Conditions
-----------------
Peri-Implantitis

Participation Criteria
=================
Eligibility Criteria
-----------------
A questionnaire was distributed to the 4716 identified subjects. 3827 questionnaires (81.15%) were returned and, hence, included in the analysis. From the sample of 3827 patients who responded to the questionnaire, 3107 (81.19%) gave their consent for access of patient files/records. Patient files/records of 2780 individuals could be collected from the treating dentists (89.48%). Out of the 2780, 900 individuals were selected by random sampling, stratifying only for the two age groups. Inclusion Criteria: Having received implants within the Swedish insurance system in 2003/2004. Being in one of the two age groups in 2003: 65-75 years and 45 - 55 years. Having answered the initial questionnaire Treating dentist provided patient files/records Exclusion Criteria: - Having died during the study period (collection of questionnaire and patient files/records)

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peri-implantitis | All subjects were provided with dental implants in 2003/2004. The clinical and radiographic examinations will be carried out in 2013. | 9-10 years following implant installation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant loss |  | 9-10 years after having received dental implants | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cross-Sectional Studies, Prevalence, Peri-Implantitis